Dr. Reddys Laboratories Ltd.

Dr. Reddys Laboratories is currently trading at Rs. 2065.95, up by 35.05 points or 1.73% from its previous closing of Rs. 2030.90 on the BSE.

The scrip opened at Rs. 2025.00 and has touched a high and low of Rs. 2068.80 and Rs. 2017.20 respectively. So far 141147 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2788.00 on 24-Jul-2017 and a 52 week low of Rs. 1888.00 on 21-May-2018.

Last one week high and low of the scrip stood at Rs. 2339.40 and Rs. 2027.10 respectively. The current market cap of the company is Rs. 34152.60 crore.

The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.05% and 28.18% respectively.

Dr. Reddy's Laboratories has launched Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg, an over-the-counter (OTC) therapeutic equivalent generic version of Nexium 24HR Capsules in the United States market as approved by the US Food and Drug Administration (USFDA).

Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg, is an OTC proton pump inhibitor used to treat frequent heartburn occurring two or more days a week in adults.

The combined market of Nexium 24HR Capsules and private label OTC Esomeprazole Magnesium products had US sales of around $311 million for the most recent twelve months ending in May 2018 according to IRI.

Dr. Reddy's Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg is available in 14 count bottles sold in cartons of 1, 2, or 3 bottles each. Each bottle contains a complete 14-day course of treatment.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.